{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:01:00Z","timestamp":1791824460348,"version":"4.3.4"},"reference-count":28,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Background: Riboflavin transporter deficiency type 2 is an ultra-rare, yet treatable, inborn error of metabolism. This autosomal recessive disorder is caused by pathogenic mutations in the SLC52A2 gene leading to progressive ataxia, polyneuropathy, and hearing and visual impairment. The early initiation of riboflavin therapy can prevent or mitigate the complications. To date, only 200 cases have been reported, mostly in consanguineous populations. The p.Gly306Arg founder mutation, identified in patients of Lebanese descent, is the most frequently reported worldwide. It was described in a homozygous state in a total of 21 patients. Therefore, studies characterizing the phenotypic spectrum of this mutation remain scarce. Methods: A retrospective review of charts of patients diagnosed with riboflavin transporter deficiency type 2 at a tertiary-care reference center in Lebanon was performed. Clinical, biochemical, and molecular profiles were analyzed and compared to reported cases in the literature. Results: A total of six patients from three unrelated families were diagnosed between 2018 and 2023. All patients exhibited the homozygous founder mutation, p.Gly306Arg, with variable phenotypes, even among family members. The median age of onset was 3 years. Diagnosis was achieved by exome sequencing at a median age of 5 years, as clinical and biochemical profiles were inconsistently suggestive. The response to riboflavin was variable. One patient treated with high-dose riboflavin recovered his motor function, while the others were stabilized. Conclusions: This study expands the current knowledge of the phenotypic spectrum associated with the p.Gly306Arg mutation in the SLC52A2 gene. Increased awareness among physicians of the common manifestations of this rare disorder is crucial for early diagnosis and treatment. In the absence of a consistent clinical or biochemical phenotype, the use of next-generation sequencing as a first-tier diagnostic test may be considered.<\/jats:p>","DOI":"10.3390\/metabo15070491","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T10:35:31Z","timestamp":1753094131000},"page":"491","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Riboflavin Transporter Deficiency Type 2: Expanding the Phenotype of the Lebanese Founder Mutation p.Gly306Arg in the SLC52A2 Gene"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1358-329X","authenticated-orcid":false,"given":"Jean-Marc T.","family":"Jreissati","sequence":"first","affiliation":[{"name":"Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9936-3737","authenticated-orcid":false,"given":"Leonard","family":"Lawandos","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7160-5693","authenticated-orcid":false,"given":"Julien T.","family":"Jreissati","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0164-4935","authenticated-orcid":false,"given":"Pascale E.","family":"Karam","sequence":"additional","affiliation":[{"name":"Inherited Metabolic Diseases Program, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Magliocca, V., Lanciotti, A., Ambrosini, E., Travaglini, L., D\u2019Ezio, V., D\u2019Oria, V., Petrini, S., Catteruccia, M., Massey, K., and Tartaglia, M. (2024). Modeling Riboflavin Transporter Deficiency Type 2: From iPSC-Derived Motoneurons to iPSC-Derived Astrocytes. Front. Cell. Neurosci., 18.","DOI":"10.3389\/fncel.2024.1440555"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108023","DOI":"10.1016\/j.pharmthera.2021.108023","article-title":"Recent Advances in Riboflavin Transporter RFVT and Its Genetic Disease","volume":"233","author":"Jin","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_3","unstructured":"Cali, E., Dominik, N., Manole, A., and Houlden, H. (2025, April 01). Riboflavin Transporter Deficiency, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK299312\/."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Zhao, S., Che, F., Yang, L., Zheng, Y., Wang, D., Yang, Y., and Wang, Y. (2022). First Report of Paternal Uniparental Disomy of Chromosome 8 with SLC52A2 Mutation in Brown-Vialetto-van Laere Syndrome Type 2 and an Analysis of Genotype-Phenotype Correlations. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.977914"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/jnnp-2020-323304","article-title":"Late-Onset Riboflavin Transporter Deficiency: A Treatable Mimic of Various Motor Neuropathy Aetiologies","volume":"92","author":"Carreau","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10545-016-9924-2","article-title":"Clinical Presentation and Outcome of Riboflavin Transporter Deficiency: Mini Review after Five Years of Experience","volume":"39","author":"Jaeger","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/iub.2541","article-title":"Impact of Natural Mutations on the Riboflavin Transporter 2 and Their Relevance to Human Riboflavin Transporter Deficiency 2","volume":"74","author":"Console","year":"2022","journal-title":"IUBMB Life"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1096-8628(20000515)92:2<117::AID-AJMG7>3.0.CO;2-C","article-title":"Brown-Vialetto-Van Laere Syndrome in a Large Inbred Lebanese Family: Confirmation of Autosomal Recessive Inheritance?","volume":"92","author":"Megarbane","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1093\/brain\/aws161","article-title":"Exome Sequencing Reveals Riboflavin Transporter Mutations as a Cause of Motor Neuron Disease","volume":"135","author":"Johnson","year":"2012","journal-title":"Brain"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/brain\/awt315","article-title":"Treatable Childhood Neuronopathy Caused by Mutations in Riboflavin Transporter RFVT2","volume":"137","author":"Foley","year":"2014","journal-title":"Brain"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ajmg.a.38530","article-title":"Riboflavin Transporter Deficiency Mimicking Mitochondrial Myopathy Caused by Complex II Deficiency","volume":"176","author":"Nimmo","year":"2018","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/mus.24224","article-title":"Mutations in Riboflavin Transporter Present with Severe Sensory Loss and Deafness in Childhood","volume":"50","author":"Srour","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhang, L., and Thyagarajan, D. (2022). Two Rare Cases of Long Surviving Riboflavin Transporter Deficiency with Co-Existing Adenosine Monophosphate Deaminase (AMP) Deficiency. Brain Sci., 12.","DOI":"10.3390\/brainsci12121605"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/jns.12619","article-title":"Development of a Functional Outcome Measure for Riboflavin Transporter Deficiency","volume":"29","author":"Fennessy","year":"2024","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40673-018-0091-0","article-title":"Successful Treatment of a Genetic Childhood Ataxia Due to Riboflavin Transporter Deficiency","volume":"5","author":"Fan","year":"2018","journal-title":"Cerebellum Ataxias"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0887-8994(02)00376-4","article-title":"A Novel Chronic Childhood Sensory Predominant Neuropathy","volume":"27","author":"Shevell","year":"2002","journal-title":"Pediatr. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1017\/S0021932009003290","article-title":"Consanguinity in Lebanon: Prevalence, Distribution and Determinants","volume":"41","author":"Barbour","year":"2009","journal-title":"J. Biosoc. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1177\/0883073816689517","article-title":"Brown-Vialetto-Van Laere Syndrome as a Mimic of Neuroimmune Disorders: 3 Cases From the Clinic and Review of the Literature","volume":"32","author":"Allison","year":"2017","journal-title":"J. Child Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e940439","DOI":"10.12659\/AJCR.940439","article-title":"A Case Report of Riboflavin Treatment and Cochlear Implants in a 4-Year-Old Girl with Progressive Hearing Loss and Delayed Speech Development: Brown-Vialetto-Van Laere Syndrome","volume":"24","author":"Piecuch","year":"2023","journal-title":"Am. J. Case Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1093\/brain\/awx231","article-title":"Clinical, pathological and functional characterization of riboflavin-responsive neuropathy","volume":"140","author":"Manole","year":"2017","journal-title":"Brain"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"135085","DOI":"10.1016\/j.jhazmat.2024.135085","article-title":"Fluoride induces immunotoxicity by regulating riboflavin transport and metabolism partly through IL-17A","volume":"476","author":"Qiao","year":"2024","journal-title":"J. Hazard. Mater."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kentab, A.Y., Alsalloum, Y., Labani, M., Hudairi, A., Hamad, M.H., Jamjoom, D.Z., Alwadei, A.H., Alhammad, R.M., and Bashiri, F.A. (2024). A rare treatable metabolic syndrome (Brown\u2013Vialetto\u2013Van Laere syndrome) masquerading as chronic inflammatory demyelinating polyneuropathy: A case report. Front. Pediatr., 12.","DOI":"10.3389\/fped.2024.1377515"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/ene.14682","article-title":"Brown-Vialetto-Van Laere and Fazio-Londe Syndromes: SLC52A3 Mutations with Puzzling Phenotypes and Inheritance","volume":"28","author":"Gayathri","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/dmcn.13084","article-title":"Auditory Neuropathy in Brown\u2013Vialetto\u2013Van Laere Syndrome Due to Riboflavin Transporter RFVT2 Deficiency","volume":"58","author":"Menezes","year":"2016","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e209969","DOI":"10.1212\/WNL.0000000000209969","article-title":"Child Neurology: Five-Year Update on Siblings With Riboflavin Transporter Deficiency: Stable Visual and Neurologic Status With Continued Riboflavin Therapy","volume":"103","author":"Culican","year":"2024","journal-title":"Neurology"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mordaunt, D., Cox, D., and Fuller, M. (2020). Metabolomics to Improve the Diagnostic Efficiency of Inborn Errors of Metabolism. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041195"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41436-018-0006-8","article-title":"Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness","volume":"21","author":"Stark","year":"2019","journal-title":"Genet. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/s41436-020-0929-8","article-title":"A cost-effectiveness analysis of genomic sequencing in a prospective versus historical cohort of complex pediatric patients","volume":"22","author":"Yeung","year":"2020","journal-title":"Genet. Med."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/7\/491\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:13:11Z","timestamp":1760033591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/7\/491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["metabo15070491"],"URL":"https:\/\/doi.org\/10.3390\/metabo15070491","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}